Recurrent, platinum-resistant ovarian carcinoma with low HER3 mRNA expression.Chemotherapy (topotecan, paclitaxel or gemcitabine) with Pertuzumab or placebo.Randomised, double-blind. Here, ERBB3 is linked to ovarian carcinoma.